PP-OVA

PP-OVA is an experimental dual-responsive nanovaccine platform designed for the cytosolic delivery of antigens to enhance cellular immune responses in cancer immunotherapy. The system utilizes mixed micelles composed of two polymers: poly(ethylene glycol)-poly(epsilon-caprolactone) (PEG-PCL) and polyethylenimine-poly(epsilon-caprolactone) (PEI-PCL). The model antigen, ovalbumin (OVA), is conjugated to the PEG-PCL component via a reducible disulfide bond (-ss-), allowing for antigen release in the reducing environment of the cytosol. The PEI-PCL component provides pH-responsiveness to facilitate endosomal escape. When loaded with the TLR9 agonist CpG ODN1826, the nanovaccine (often referred to as PP-OVA/CpG) promotes dendritic cell maturation and antigen cross-presentation, leading to potent cytotoxic T-lymphocyte responses. Preclinical studies have demonstrated its efficacy in treating ectopic and metastatic B16-OVA melanoma, especially when combined with anti-PD-1 therapy.

Other names

PEG-PCL/PEI-PCL-OVA nanovaccine